YD Bio Ltd is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for YD Bio Ltd is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.
YD Bio Ltd valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders1 buying, 0 selling3 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds7 adding, 1 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
YD Bio Ltd's trailing-twelve-month revenue grew 16.9% year on year, with a free-cash-flow margin of -1346.6%. Where it stands out: long-term debt as % of assets of 0.0% ranks 2 of 35 life sciences tools & services companies we cover. Where it lags: change in growth rate of -28.8pp ranks 54 of 54 life sciences tools & services companies we cover.
Current signal Capital expenditure surging: TTM capex grew 1822% year over year and now absorbs 241.3% of revenue.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Fast growth. Revenue grew 16.9% over the last 12 months, against a median of 6.9% for life sciences tools & services companies we cover.
- Net cash. Cash exceeds long-term debt by $0.0bn.
Things to watch
- Growth slowing. The growth rate is 28.8 points lower than a quarter earlier.
- Loss-making. Operating margin is -883.3%: costs exceed revenue.
- Margins narrowing. Operating margin is down 596.9 points on a year ago.
- Burning cash. Free cash flow was -1346.6% of revenue over the last 12 months.
- Heavy stock-based pay. Stock pay equals 75.1% of revenue, against a median of 4.4% for life sciences tools & services companies we cover: a real cost that cash-flow figures leave out.
- Share dilution. Diluted shares rose 3.1% in a year.
Price chart
- 1 day+5.4%
- 1 week+4.2%
- 1 month-22.4%
- This year-51.0%
- 1 year-44.4%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $596,817
- Operating margin
- -883.3%
- Net margin
- -1392.6%
- EPS (TTM, diluted)
- $-0.12
Growth
- Revenue growth
- +16.9%
- Change in growth rate
- −28.8 pts
- Share count change
- +3.1%
Cash
- Free cash flow (TTM)
- -$8M
- FCF margin
- -1346.6%
- Stock pay % of revenue
- 75.1%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for YDES from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value YD Bio Ltd as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.0 ~$0.0–$0.1 | Left out: out of range vs price (0.00x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare YD Bio Ltd with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Valuation multiples over time Market data may be delayed
| At fiscal year end | 2025 |
|---|---|
| Share price | $12.19 |
| Market value | $813m |
| + Net debt (− = net cash) | −$6m |
| Enterprise value | $807m |
| Multiples | |
| Price / sales | n/m |
| Price / earnings | — |
| Price / free cash flow | — |
| EV / EBITDA | — |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for YD Bio Ltd: too few analysts cover it.
Positioning
- Short interest
- 1.2% of tradable shares
- Days to cover
- 0.4 at average volume
- Short interest, 1 month
- +347% to October 15, 2026
- Held by institutions
- 0% of shares
- Held by insiders
- 80.2% of shares
- Employees
- 13 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2026 to date |
|---|---|
| Return | |
| YDES | −51% |
| Industry peers (median) | +16% |
| S&P 500 | +11% |
| Months that ended higher | |
| YDES | 27% |
| S&P 500 | 46% |
| Largest fall from a high during the year | |
| YDES | −85% |
| S&P 500 | −9% |
Worst fall since August 26, 2025: 92% from September 12, 2025 to July 2, 2026. Getting back needed a 1116% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $1.90 – $15.42
- From 52-week high
- −61.3%
- vs 50-day average
- +15.9%
- vs 200-day average
- +8.6%
- Volatility (1 year)
- 135%
- Beta vs S&P 500
- 0.12
YD Bio Ltd in five measures
Fundamentals
Financial statements
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|
| Income | |||
| Revenue | 350 | 510 | 597 |
| Gross profit | 153 | 155 | 167 |
| EBITDA | −7 | −1,452 | −5,255 |
| Operating income | −10 | −1,462 | −5,272 |
| Net income | 14 | −1,412 | −8,311 |
| Diluted EPS | $0.00 | −$0.02 | −$0.12 |
| Growth (year on year) | |||
| Revenue | — | +45.8% | +16.9% |
| Net income | — | <−999% | — |
| Margins | |||
| Gross margin | 43.8% | 30.4% | 28.1% |
| EBITDA margin | −2.1% | −284.5% | −880.6% |
| Operating margin | −2.8% | −286.5% | −883.3% |
| Net margin | 3.9% | −276.6% | <−999% |
| Free-cash-flow margin | −16.0% | −254.3% | <−999% |
| Cash flow | |||
| Cash from operations | −56 | −1,223 | −6,597 |
| Capital spending | 0 | 75 | 1,440 |
| Free cash flow | −56 | −1,298 | −8,037 |
| Stock-based pay | — | — | 448 |
| Free cash flow after stock pay | — | — | −8,485 |
| Balance sheet | |||
| Cash | 87 | 3,132 | 6,008 |
| Total debt | 0 | 0 | 7 |
| Net debt (negative = net cash) | −87 | −3,132 | −6,001 |
| Diluted shares | 65m | 65m | 67m |
Financial health
- Short-term assets cover short-term liabilities $10m of assets due within a year against $2m of liabilities due within a year.
- Short-term assets cover long-term liabilities $10m short-term assets against $15m of longer-dated liabilities.
- More cash than debt $6m of cash against $6,764 of debt.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$7m of operating cash flow against $6,764 of debt.
- Operating profit covers interest at least five times over No material interest expense reported.
Dividends, buybacks and capital spending
- Diluted share count
- +3.1%
- year over year
- R&D spending
- 268.4%
- of revenue
- Days sales outstanding
- 102 days
- receivables vs revenue
Competitors: side by side with peers
| Last 12 months unless stated | YDES | ISPC | QSI | BGLC | ACON | SEER | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $596817 | $466302 | $2m | $3m | $83769 | $14m | $229m |
| Revenue growth, last 12 months | 16.9% | −92.1% | −53.0% | −67.3% | 33.1% | −12.7% | 6.9% |
| Revenue growth, 3-year average | — | −64.1% | 51.8% | −32.9% | 0.2% | −5.1% | 2.9% |
| Revenue growth, latest quarter | — | −78.7% | −41.8% | −96.6% | 30.5% | −23.4% | 8.5% |
| Gross margin | 28.1% | −98.0% | 35.0% | 12.3% | 21.8% | 47.7% | 51.9% |
| Operating margin | −883.3% | <−999% | <−999% | −81.8% | <−999% | −498.2% | −14.3% |
| Operating margin, 3-year average | — | −768.0% | <−999% | −45.3% | <−999% | −575.4% | −22.4% |
| Net margin | <−999% | <−999% | <−999% | −82.4% | <−999% | −478.0% | −16.1% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | −27.1% | <−999% | −305.1% | 1.3% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | −27.3% | <−999% | −311.1% | −2.2% |
| Free-cash-flow margin, 3-year average | — | −549.8% | <−999% | −29.5% | <−999% | −335.4% | 0.6% |
| Stock pay / revenue | 75.1% | 1.0% | 693.5% | — | 152.7% | 74.3% | 4.4% |
| Change in share count | 3.1% | — | 31.2% | — | — | 0.2% | 1.0% |
Peer comparison
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 16.9% | 6.9% | 14 of 54 |
| Change in growth rate Growth | -28.8pp | +0.4pp | 54 of 54 |
| Gross margin Profitability | 28.1% | 52.0% | 40 of 45 |
| Operating margin Profitability | -883.3% | -14.3% | 49 of 52 |
| Net margin Profitability | -1392.6% | -12.2% | 51 of 54 |
| Free-cash-flow margin Cash generation | -1346.6% | -1.3% | 51 of 54 |
| Stock pay as % of revenue Cash generation | 75.1% | 4.4% | 51 of 53 |
| Long-term debt as % of assets Balance sheet | 0.0% | 26.3% | 2 of 35 |
| Change in share count Balance sheet | 3.1% | 1.0% | 33 of 46 |
| Days sales outstanding Balance sheet | 102 days | 62 days | 45 of 48 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
Who owns it
Funds buying and selling- Reported value
- $635,571
- Institutions reporting
- 11
- Shares held vs prior quarter
- ▲ 77.1%
- Positions opened / closed
- 3 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Garrett Wealth Advisory Group, LLC | $190,418 | 85K | 30.0% | New |
| Geode Capital Management, LLC | $141,106 | 63K | 22.2% | ▲ 4.1% |
| Cypress Capital Management LLC (WY) | $75,803 | 34K | 11.9% | ▲ 9.8% |
| Cerity Partners LLC | $72,914 | 32K | 11.5% | 0.0% |
| Citadel Advisors LLC | $67,739 | 30K | 10.7% | ▲ 54.8% |
| Jane Street Group, LLC | $48,202 | 21K | 7.6% | New |
| UBS Group AG | $27,864 | 12K | 4.4% | ▲ 6.5% |
| Wolverine Asset Management LLC | $10,994 | 5K | 1.7% | 0.0% |
| Morgan Stanley | $360 | 0K | 0.1% | ▼ 28.3% |
| Wells Fargo & Company | $169 | 0K | 0.0% | New |
| FMR LLC | $2 | 0K | 0.0% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not YD Bio Ltd's complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Shen Ethan Phd CEO | September 14, 2026 | Buy | 12,700 | $3.85 | $48,895 |
| Shen Ethan Phd CEO | September 9, 2026 | Buy | 3,100 | $3.93 | $12,183 |
| Shen Ethan Phd CEO | September 4, 2026 | Buy | 18,378 | $3.67 | $67,447 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
YD Bio Ltd in brief
- What does YD Bio Ltd do?
- YD Bio Ltd is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
- What is YD Bio Ltd's stock ticker?
- YD Bio Ltd trades under the ticker YDES on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- What is YD Bio Ltd's revenue, and how fast is it growing?
- Over its most recent trailing twelve months, YD Bio Ltd reported revenue of $596,817, 16.9% higher than a year earlier, according to its SEC filings.
- What is YD Bio Ltd's free cash flow?
- YD Bio Ltd's free-cash-flow margin is -1346.6% of revenue over the trailing twelve months, ranking 51 of the 54 life sciences tools & services companies we cover.
- Who are YD Bio Ltd's largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Garrett Wealth Advisory Group, LLC, Geode Capital Management, LLC and Cypress Capital Management LLC (WY). 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- What is YD Bio Ltd's market cap?
- On December 31, 2025, YD Bio Ltd's market capitalisation was about $813M and net debt of -$6M. Market figures come from third-party market data and may be delayed.
- Who are YD Bio Ltd's competitors?
- In our Life Sciences Tools & Services peer group, the companies closest to YD Bio Ltd are Ispecimen Inc., Quantum-si Inc, Bionexus Gene Lab Corp, Aclarion, Inc. and Seer, Inc. The side-by-side comparison below sets their revenue, margins and growth against YD Bio Ltd's.
- Are insiders buying or selling YD Bio Ltd stock?
- Over the last 12 months, YD Bio Ltd's directors and officers reported 3 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
Follow research on YD Bio Ltd
New research on the companies we cover arrives in the weekly email. Free, one email a week.